LDCT Lung Screening for Early Detection of Lung Cancer

Overseen By Darcy Doege, RN

Age: 18 - 65

Sex: Any

Trial Phase: Academic

Sponsor: Daniel Carrizosa

Disqualifiers: Lung cancer, CT contraindication, pregnancy

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Approved in 3 Jurisdictions This treatment is already approved in other countries

Compensation: Varies

Number of Visits: 4

1160 Participants Needed

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial explores a new method to detect lung cancer early in high-risk individuals. It tests mobile low-dose CT scans (Mobile Low-dose Computed Tomography (LDCT) Screening), which are special X-rays that use less radiation, to determine if starting screenings at a younger age is beneficial. The trial targets individuals aged 40-54 who have a history of heavy smoking, either currently smoking or having quit within the last 15 years. The aim is to assess whether earlier screening can improve survival rates for those with a significant smoking history. As an unphased trial, this study provides a unique opportunity to contribute to groundbreaking research that may lead to earlier detection and better outcomes for high-risk individuals.

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications.

What prior data suggests that this screening method is safe for early detection of lung cancer?

Research shows that Low-dose CT (LDCT) Screening is safe for people. In previous studies, LDCT has been used to detect lung cancer early, aiding in earlier treatment and reducing deaths. For instance, the National Lung Screening Trial (NLST) found that LDCT can lower lung cancer deaths in high-risk individuals.

The screening is generally easy for most people to handle, with no serious side effects. It uses a small amount of radiation to image the lungs, much less than a regular CT scan, making it safer for repeated use.

Some studies have shown that LDCT is very effective at finding lung cancer early. One study found that it correctly identified 97 out of 100 lung cancer cases, demonstrating its effectiveness with minimal harm.

Overall, LDCT Screening has proven to be a safe and effective method for checking lung cancer in at-risk individuals. ^{1 2 3 4 5}

Why are researchers excited about this trial?

Researchers are excited about Mobile Low-dose Computed Tomography (LDCT) Screening for lung cancer detection because it offers a more accessible and potentially earlier diagnosis compared to traditional methods, like standard chest X-rays or fixed-location CT scans. Unlike these conventional options, mobile LDCT units can travel to underserved areas, making screenings more available to populations with limited access to healthcare facilities. This early detection is crucial as it can lead to earlier interventions, improving outcomes and potentially saving more lives.

What evidence suggests that Mobile Low-dose CT Screening is effective for early detection of lung cancer?

Research has shown that Mobile Low-dose CT (LDCT) screening, which participants in this trial will receive, effectively detects lung cancer early. In a large study called the National Lung Screening Trial (NLST), LDCT screening reduced lung cancer deaths by 20% compared to regular chest X-rays. Another study in Europe found similar results, demonstrating that LDCT can save lives by detecting cancer sooner. LDCT is particularly beneficial for individuals with a long history of smoking, as it increases the likelihood of finding cancer when it is easier to treat. Early detection leads to better survival rates, making LDCT a promising tool for those at high risk. ^{1 2 3 6 7}

Who Is on the Research Team?

Daniel Carrizosa, MD

Principal Investigator

LCI

Are You a Good Fit for This Trial?

This trial is for people aged 40-54 who have a significant smoking history (at least 30 pack years), are currently smoking or quit within the last 15 years, and can understand English/Spanish. They must consent to share health information and follow study procedures. Those with past lung cancer diagnosis, CT scan contraindications, or pregnancy cannot join.

Inclusion Criteria

Written informed consent and HIPAA authorization for release of personal health information. NOTE: HIPAA authorization may be included in the informed consent or obtained separately.

I am between 40 and 54 years old.

I have smoked for 30 or more years and quit less than 15 years ago, if at all.

Exclusion Criteria

Any known contraindication to having a low-dose CT Scan.

Known pregnancy.

I was diagnosed with lung cancer within the last 5 years.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

1 day

1 visit (in-person)

Initial Screening (T0)

Participants undergo their first mobile low-dose CT screening to evaluate lung cancer diagnosis rate

1 day

1 visit (in-person)

Subsequent Screenings (T1 and T2)

Participants undergo subsequent mobile low-dose CT screenings to evaluate lung cancer diagnosis rate and positive screening rate

up to 24 months

2 visits (in-person)

Follow-up

Participants are monitored for safety and effectiveness after screenings

up to 24 months

What Are the Treatments Tested in This Trial?

Interventions

• Mobile Low-dose Computed Tomography (LDCT) Screening

Trial Overview

The study tests if lowering the age for Low-dose Computed Tomography (LDCT) screening can help detect lung cancer earlier in smokers or recent quitters aged 40-54. This follows evidence that LDCT improves survival rates in older individuals.

How Is the Trial Designed?

Group I: Single Arm Experimental Treatment 1 Intervention

Mobile Low-dose Computed Tomography (LDCT) Screening

Mobile Low-dose Computed Tomography (LDCT) Screening is already approved in United States, European Union, Canada for the following indications:

Approved in United States as Low-dose CT Screening for:

• Lung cancer screening for high-risk populations aged 55 and older
• Experimental use for ages 40-54 in specific studies

Approved in European Union as LDCT Screening for:

• Lung cancer screening for high-risk populations aged 55 and older

Approved in Canada as Low-dose CT Screening for:

• Lung cancer screening for high-risk populations aged 55 and older

Who Is Running the Clinical Trial?

Daniel Carrizosa

Lead Sponsor

Trials

1

Recruited

1,200+

Wake Forest University Health Sciences

Lead Sponsor

Trials

1,432

Recruited

2,506,000+

Leon Levine Foundation

Collaborator

Trials

1

Recruited

1,200+

Published Research Related to This Trial

In a study of 13,831 smokers aged 55-74, screening for lung cancer using low-dose chest CT (LDCT) showed a significant reduction in lung cancer mortality after the first year for those with obstructive lung disease (OLD), with a hazard ratio of 0.63 (indicating a 37% reduction in risk).

The number needed to screen to prevent one lung cancer death in patients with OLD was 108, which is more favorable compared to 218 for those without OLD, suggesting that LDCT screening is particularly beneficial for high-risk individuals with OLD.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Exploring the Impact of Lung Cancer Screening on Lung Cancer Mortality of Smokers With Obstructive Lung Disease: Analysis of the NLST-ACRIN Cohort. de-Torres, JP., Wisnivesky, JP., Bastarrika, G., et al.[2021]

Low-dose computed tomography (LDCT) screening can detect lung cancers at earlier stages, leading to a 20% reduction in cancer-related deaths.

While LDCT screening shows significant potential benefits for certain patients, there are still many unanswered questions regarding its practical application in clinical settings.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Computed tomography screening for lung cancer: where are we now? Christensen, JD., Tong, BC.[2021]

In a study of 121 patients who underwent low-dose computed tomography (LDCT) screening for lung cancer, the overall adherence rate to follow-up scans was only 59.1%, indicating a need for improved compliance with screening guidelines.

Patients with more concerning findings (Lung-RADS score 2) were 2.43 times more likely to adhere to follow-up scans compared to those with less concerning findings (Lung-RADS score 1), while African American patients showed lower odds of adherence, highlighting potential socioeconomic disparities in lung cancer screening compliance.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Patient Adherence in an Academic Medical Center's Low-dose Computed Tomography Screening Program. Mortman, KD., Devlin, J., Giang, B., et al.[2023]

Annual low-radiation-dose computed tomography (LDCT) screening can significantly reduce lung cancer mortality in high-risk individuals, but its implementation requires careful planning to maximize benefits and minimize harms.

The American Thoracic Society and American College of Chest Physicians provide a framework for developing LDCT screening programs, outlining essential strategies for planning, implementation, and maintenance to ensure these programs are safe, effective, and sustainable.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

An official American Thoracic Society/American College of Chest Physicians policy statement: implementation of low-dose computed tomography lung cancer screening programs in clinical practice. Wiener, RS., Gould, MK., Arenberg, DA., et al.[2022]

Oncology nurse navigation significantly improved provider education about low-dose computed tomography (LDCT) lung cancer screening, leading to better discussions about tobacco cessation and increased adherence to screening protocols.

During a five-month intervention involving 133 eligible patients, the time taken for providers and patients to be notified about LDCT results was significantly reduced, indicating enhanced efficiency in the screening process.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Low-Dose Computed Tomography: Effects of Oncology Nurse Navigation on Lung Cancer Screening. Watson, J., Broome, ME., Schneider, SM.[2021]

Low-dose computed tomography (LDCT) effectively detects asymptomatic lung cancer in high-risk individuals, with a lung cancer detection rate of 1.21% in the high-risk group and 2.01% in heavy smokers, compared to 0.51% overall in the study of 1551 adults.

The study highlights that the detection rate of lung cancer increases with the number of risk factors, demonstrating LDCT's potential as a sensitive screening tool for lung cancer in populations with varying levels of risk.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

[Application value of low-dose computed tomography for the screening of lung cancer in high-risk group]. Lei, Y., Chen, BJ., Zeng, L., et al.[2016]

The Lung Cancer Causal Model (LCCM) developed from a study of 218 subjects effectively distinguishes between malignant and benign lung nodules using key factors like nodule and vessel counts and smoking history, improving predictive accuracy over existing models.

LCCM can identify 30% of benign nodules without misclassifying cancerous ones, potentially reducing unnecessary follow-ups and procedures in lung cancer screening.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Feasibility of lung cancer prediction from low-dose CT scan and smoking factors using causal models. Raghu, VK., Zhao, W., Pu, J., et al.[2022]

Low-dose computed tomography (LDCT) screening significantly detects more stage I lung cancers and total lung cancers compared to chest X-ray or usual care in high-risk individuals over 49 years old with smoking exposure.

While LDCT screening reduces lung cancer-specific mortality, it does not lower overall mortality rates and is associated with a higher rate of false positives.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

A meta-analysis: is low-dose computed tomography a superior method for risky lung cancers screening population? Fu, C., Liu, Z., Zhu, F., et al.[2017]

In a study of 272 patients screened for lung cancer using low dose computed tomography (LDCT), the lung cancer detection rate was 2.2%, which aligns with findings from the National Lung Screening Trial, indicating the efficacy of LDCT in identifying lung cancer.

The implementation of LDCT screening highlighted the importance of thorough pre-screening evaluations and careful scanning protocols to ensure patient safety, with a mean radiation dose of 3.12 mGy achieved through techniques like tube current modulation.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Low-dose Lung Cancer Screening at an Academic Medical Center: Initial Experience and Dose Reduction Strategies. Ahmed, A., Verma, N., Barreto, I., et al.[2019]

Lung cancer screening using low-dose computed tomography (LDCT) can reduce lung cancer mortality by 20% in high-risk populations, based on a class I clinical trial.

However, there are significant concerns about LDCT screening, including risks from radiation exposure, the potential for overdiagnosis of non-threatening tumors, and high rates of false positives, which can lead to unnecessary anxiety and procedures.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Effective use of low-dose computed tomography lung cancer screening. Jeffers, CD., Pandey, T., Jambhekar, K., et al.[2016]

In a study involving 8649 asymptomatic volunteers aged 50 to 75 with significant smoking histories, lung cancer screening using low-dose computed tomography (LDCT) detected lung cancer in 107 patients (1.24%), indicating the program's effectiveness in identifying cases early.

The majority of lung cancers were diagnosed at an early stage (Stage I non-small cell lung cancer in 79% of surgical patients), and the screening program had no perioperative deaths, highlighting its safety and potential for curative treatment.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Results of an open-access lung cancer screening program with low-dose computed tomography: the Gdańsk experience. Rzyman, W., Dziedzic, R., Jelitto-Górska, M., et al.[2019]

The LungSEARCH trial, involving 1568 participants, tested a sequential lung cancer screening strategy using sputum samples to identify high-risk individuals for further testing, but it did not significantly increase the diagnosis of early-stage lung cancer compared to standard methods.

The overall sensitivity of sputum testing was low at 40.5%, and many lung cancers (55%) had normal sputum results, indicating that this approach may not be effective for improving lung cancer screening outcomes.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Sequential screening for lung cancer in a high-risk group: randomised controlled trial: LungSEARCH: a randomised controlled trial of Surveillance using sputum and imaging for the EARly detection of lung Cancer in a High-risk group. Spiro, SG., Shah, PL., Rintoul, RC., et al.[2020]

Targeting lung cancer screening using low-dose computed tomography (LDCT) to individuals at higher risk for lung cancer mortality can prevent more deaths, with benefits ranging from 1.2 to 9.5 deaths prevented per 10,000 person-years based on risk deciles.

However, the overall gains in life-years and quality-adjusted life-years (QALYs) are modest, with similar cost-effectiveness ratios across risk groups, suggesting that while risk-targeting improves early mortality outcomes, it does not significantly enhance overall efficiency in terms of life extension or cost-effectiveness.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Risk-Targeted Lung Cancer Screening: A Cost-Effectiveness Analysis. Kumar, V., Cohen, JT., van Klaveren, D., et al.[2022]

Citations

1.

pmc.ncbi.nlm.nih.gov

pmc.ncbi.nlm.nih.gov/articles/PMC7216453/

Initial Results from Mobile Low‐Dose Computerized ...

Using low‐dose helical computed tomography (LDCT) screening, the National Lung Screening Trial (NLST) demonstrated a 20% improvement in tumor‐specific survival ...

2.

pmc.ncbi.nlm.nih.gov

pmc.ncbi.nlm.nih.gov/articles/PMC9311401/

Low‐dose computed tomography lung cancer screening

The US National Lung Screening Trial reported a 20% overall reduction in lung cancer mortality when comparing LDCT to chest X‐ray, and the Nederlands‐Leuvens ...

3.

sciencedirect.com

sciencedirect.com/science/article/pii/S0959804925003521

Review Current evidence of low-dose CT screening benefit

Early results showed higher lung cancer detection rates in people who have never smoked with a family history of lung cancer (1.7 %) than in ...

4.

bmccancer.biomedcentral.com

bmccancer.biomedcentral.com/articles/10.1186/s12885-025-13710-2

The feasibility and cost-effectiveness of implementing mobile ...

Low-dose computed tomography (LDCT) significantly increases early detection rates of lung cancer and reduces lung cancer-related mortality by 20 ...

5.

thelancet.com

thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00082-8/fulltext

Low-dose CT for lung cancer screening in a high-risk ...

Low-dose CT screening reduces lung cancer mortality. In advance of planned national lung cancer screening programmes, research is needed to ...

6.

pmc.ncbi.nlm.nih.gov

pmc.ncbi.nlm.nih.gov/articles/PMC4662564/

Assessing the benefits and harms of low-dose computed ...

In 2011, the National Lung Screening Trial (NLST) reported that LDCT screening significantly reduced mortality from lung cancer in a high risk population. This ...

7.

atsjournals.org

atsjournals.org/doi/10.1164/rccm.201508-1671ST

Implementation of Low-Dose Computed Tomography Lung ...

The National Lung Screening Trial (NLST) demonstrated that LDCT screening of high-risk individuals can reduce lung cancer death (1). On average, NLST ...